Spirometry and GOLD staging
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
COPD cannot be diagnosed on symptoms, a chest X-ray or a smoking history. It requires a breathing test, and a large share of people carrying the label have never had one.
The test also produces the staging number people worry about, which turns out to be only one of three things that guide treatment.
Related pages: COPD (chronic lung disease)
The bottom line
- COPD is defined by a post-bronchodilator FEV1/FVC ratio below 0.70.
- GOLD 1 to 4 grade the severity of airflow limitation by FEV1.
- Treatment is guided by symptoms and exacerbations, not by the GOLD number alone.
- Spirometry must be done after a bronchodilator to distinguish COPD from asthma.
- Alpha-1 antitrypsin should be tested at least once in everyone diagnosed.
- Whether a fixed 0.70 ratio over-diagnoses in older people.
- How best to detect early disease before spirometry becomes abnormal.
- How to raise spirometry rates before diagnosis.
The story, step by step
- 1. The test ()
- 2. The threshold ()
- 3. The stages ()
- 4. Beyond the number ()
- 5. The rest of the workup ()
What the evidence labels mean
What spirometry measures
What happens
Blow out hard and keep going.
What the research shows
- You breathe in fully, then blow out as hard and as long as you can into a tube, usually three times.
- FVC is the total volume blown out. FEV1 is the volume in the first second.
- In healthy lungs, most of the air comes out in that first second, so the FEV1/FVC ratio is high.
- In obstruction, air leaves slowly, so FEV1 falls more than FVC and the ratio drops.
- The test is effort-dependent and takes practice. Poor technique produces false results, which is why it is repeated and why trained staff matter.
- It is uncomfortable rather than painful, and many people cough during it.
Why it matters
Getting a good blow is harder than it sounds, and an under-effort result can label someone with a disease they do not have, or miss one they do.
What's still uncertain
- How much quality varies between settings.
- Whether home spirometry will become reliable enough.
Read more
- NHLBI: COPD diagnosisGovernment
- MedlinePlus: COPDGovernment
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
Next: The threshold
What defines COPD
What happens
A ratio below 0.70, after a bronchodilator.
What the research shows
- COPD is defined by a post-bronchodilator FEV1/FVC ratio below 0.70, together with symptoms and a history of exposure.
- Post-bronchodilator means after inhaling a reliever, which is what separates COPD from asthma. Asthma largely reverses; COPD does not.
- A pre-bronchodilator test alone cannot make the diagnosis, and this step is frequently skipped.
- The fixed 0.70 cut-off is simple and is debated, because the ratio falls naturally with age, so it may over-diagnose in older people and under-diagnose in younger ones.
- Some guidelines prefer the lower limit of normal, adjusted for age, sex and height.
- Symptoms matter too. An abnormal ratio in someone with no symptoms and no exposure is not automatically COPD.
Why it matters
Without the post-bronchodilator step, asthma and COPD cannot be separated, and the treatments that follow differ.
What's still uncertain
- Whether the fixed ratio should be replaced.
- How to handle abnormal spirometry in asymptomatic people.
Read more
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
- NHLBI: COPD diagnosisGovernment
- NHLBI: AsthmaGovernment
Next: The stages
GOLD 1 to 4
What happens
Severity of airflow limitation.
What the research shows
- Once the ratio confirms obstruction, FEV1 as a percentage of predicted gives the grade.
- GOLD 1, mild: FEV1 80 percent or more of predicted. Often no awareness of any problem.
- GOLD 2, moderate: 50 to 79 percent. Breathlessness on exertion usually appears here, and this is where most people are diagnosed.
- GOLD 3, severe: 30 to 49 percent. Greater limitation and more frequent flare-ups.
- GOLD 4, very severe: below 30 percent. Risk of chronic respiratory failure.
- Predicted values are based on age, sex, height and ethnicity, so the percentage compares you with people of similar build.
Why it matters
The grade describes airflow and not how someone feels. People at GOLD 2 are sometimes more limited than people at GOLD 3, which surprises everyone.
What's still uncertain
- How well FEV1 predicts outcomes compared with composite scores.
- Whether predicted-value equations are appropriate across populations.
Read more
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
- NHLBI: COPD diagnosisGovernment
- CDC: COPDGovernment
Next: Beyond the number
Symptoms and exacerbations
What happens
What actually guides treatment.
What the research shows
- Current guidance assesses three things: the spirometry grade, the symptom burden, and the exacerbation history.
- Symptoms are measured with simple questionnaires: the mMRC breathlessness scale, from 0 to 4 based on what activity brings it on, or the CAT score covering cough, phlegm, chest tightness, activity, confidence, sleep and energy.
- Exacerbation history is the strongest single predictor of future exacerbations. Two or more in a year, or one needing hospital admission, marks someone as high risk.
- People are then placed in groups, currently A, B and E, which determine the starting inhaler treatment.
- The practical point is that treatment follows symptoms and flare-ups, not the FEV1 number.
- Composite indices combining breathlessness, exercise capacity, airflow and body mass predict survival better than spirometry alone.
Why it matters
Being told a stage without being asked about flare-ups misses the thing that most determines what happens next.
What's still uncertain
- How well the ABE grouping performs in practice.
- Which composite scores are most useful clinically.
Read more
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
- NHLBI: COPD diagnosisGovernment
- American Lung AssociationNonprofit
Next: The rest of the workup
What else gets checked
What happens
Including one test that is routinely missed.
What the research shows
- Alpha-1 antitrypsin level, which guidance says should be measured at least once in everyone diagnosed with COPD. It is substantially under-tested, and finding it changes family screening and may change treatment.
- A chest X-ray, which does not diagnose COPD but excludes other causes and may show hyperinflation.
- A CT scan where emphysema distribution matters, for lung cancer screening in eligible smokers, or before surgical procedures.
- Oxygen saturation, and arterial or capillary blood gases where it is low or the disease is advanced.
- Full blood count, including eosinophils, which help decide whether inhaled steroids are likely to help.
- An assessment for other conditions: heart disease, anxiety and depression, osteoporosis, and sleep apnea.
Why it matters
Ask whether alpha-1 antitrypsin has been checked. It is a single blood test, guidelines recommend it once for everyone, and most people never receive it.
What's still uncertain
- How to raise alpha-1 testing rates.
- How best to use eosinophil counts in treatment decisions.